Old Web
English
Sign In
Acemap
>
authorDetail
>
Caroline Chen
Caroline Chen
Astellas Pharma
Pathology
Medicine
Refractory
Oncology
Myeloid leukemia
3
Papers
16
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (3)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
A phase II, multicenter, open-label study of YM155 plus docetaxel in subjects with stage III (unresectable) or stage IV melanoma.
2017
Journal of Clinical Oncology
Joyce Steinberg
Agop Y. Bedikian
D. Scott Ernst
Bartosz Chmielowski
Bruce G. Redman
Anne Keating
Fei Jie
Caroline Chen
Jeffrey S. Weber
Ragini R. Kudchadkar
Show All
Source
Cite
Save
Citations (3)
An open-label, randomized phase III study of gilteritinib versus salvage chemotherapy in relapsed or refractory FLT3 mutation-positive acute myeloid leukemia.
2017
Journal of Clinical Oncology
Alexander E. Perl
Jorge E. Cortes
Stephen A. Strickland
Ellen K. Ritchie
Andreas Neubauer
Giovanni Martinelli
Tomoki Naoe
Arnaud Pigneux
Philippe Rousselot
Christoph Röllig
Maria R. Baer
Richard A. Larson
Angela Joubert James
Caroline Chen
Lei Shu
Nahla Hasabou
Erkut Bahceci
Show All
Source
Cite
Save
Citations (9)
A phase 3, open-label, randomized study of the FLT3 inhibitor gilteritinib versus salvage chemotherapy in adults with first relapse or primary refractory FLT3 mutation-positive acute myeloid leukemia.
2016
Journal of Clinical Oncology
Alexander E. Perl
Jorge E. Cortes
Stephen A. Strickland
Ellen K. Ritchie
Andreas Neubauer
Giovanni Martinelli
Tomoki Naoe
Arnaud Pigneux
Philippe Rousselot
Christoph Röllig
Maria R. Baer
Richard A. Larson
Angela Joubert James
Caroline Chen
Lei Shu
Nahla Hasabou
Erkut Bahceci
Show All
Source
Cite
Save
Citations (4)
1